Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | G1T38 + Letrozole |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| G1T38 | Lerociclib | CDK4/6 Inhibitor 14 | Lerociclib (G1T38) is a selective CDK4/6 inhibitor, which results in cell cycle arrest and tumor cell death (PMID: 32130619). | |
| Letrozole | Femara | Letrozol | Aromatase Inhibitor 3 | Femara (letrozole) is an aromatase inhibitor, which inhibits estrogen synthesis, and is approved for postmenopausal women with hormone receptor positive breast cancer (FDA.gov). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05712941 | Phase III | G1T38 + Letrozole Letrozole | Comparison of Letrozole With Lerociclib Versus Letrozole With Placebo Control in Patients With Advanced/Metastatic or Recurrent, Grade 1 or Grade 2 Endometrial Cancer | Withdrawn | 0 | |
| NCT05085002 | Phase II | G1T38 + Letrozole Fulvestrant + G1T38 | A Study of Lerociclib in Participants With Advanced Breast Cancer | Terminated | USA | ITA | BEL | 3 |